c-Mer Tyrosine Kinase

A receptor tyrosine kinase that transduces signals from EXTRACELLULAR MATRIX to the CYTOPLASM by binding ligands such as GALECTIN 3. It regulates many physiologic processes that include cell survival, migration, differentiation, and PHAGOCYTOSIS of apoptotic cells and ROD PHOTORECEPTORS in the RETINAL PIGMENT EPITHELIUM. Mutations in the MERTK gene are associated with type 38 RETINITIS PIGMENTOSA; it also plays a critical role as an inhibitor of TOLL-LIKE RECEPTORS signaling.

Also Known As:

Networked: 454 relevant articles (42 outcomes, 55 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Earp, H Shelton: 32 articles (03/2024 - 02/2003)
2.	Graham, Douglas K: 31 articles (03/2024 - 05/2010)
3.	Wang, Xiaodong: 27 articles (03/2024 - 05/2013)
4.	DeRyckere, Deborah: 26 articles (03/2024 - 05/2013)
5.	Frye, Stephen V: 21 articles (03/2024 - 05/2013)
6.	Birge, Raymond B: 17 articles (04/2024 - 02/2008)
7.	Tabas, Ira: 15 articles (01/2023 - 08/2008)
8.	Rothlin, Carla V: 14 articles (02/2023 - 08/2014)
9.	Davra, Viralkumar: 11 articles (04/2024 - 01/2016)
10.	Ghosh, Sourav: 10 articles (02/2023 - 08/2014)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2018 - "These observations suggest that therapeutic strategies cotargeting both AXL and MERTK could be highly beneficial in a variety of tumor types where both receptors are expressed, leading to improved survival for patients with lethal malignancies. " 01/01/2022 - "Furthermore, Mertk KO mice display improved anti-tumor immunity. " 02/01/2023 - "Our results indicated that the protocatechuate-TAASGVRSMH, thiazole-2-amido-TAASGVRSMH, and vanillate-TAASGVRSMH conjugates may be furthered developed for in vitro and in vivo studies as novel tumor targeting compounds for tumor cells over-expressing BRAF V600E, while di-theaninate-amido-TAASGVRSMH and thiazole-2-amido-TAASGVRSMH conjugates may be developed for targeting MERTK receptors. " 10/19/2022 - "Furthermore, similar to unconjugated anti-MerTK, PEGylated anti-MerTK antibody triggered type I IFN response and exhibited antitumor effect in syngeneic mouse tumor studies. " 01/01/2022 - "Studies are underway to develop small-molecule chemicals that inhibit MERTK as cancer immunotherapeutic agents, but these efforts are in their early stages. "
2.	Inflammation (Inflammations) 06/07/2016 - "We show here that SPM biosynthesis is increased and inflammation resolution is improved in a new mouse model in which endogenous MerTK was replaced with a genetically engineered variant that is cleavage-resistant (Mertk(CR)). " 11/18/2016 - "Our studies reveal that IL-37 limits runaway inflammation initiated by MSU crystal-induced immune responses, partly in a Mertk-dependent fashion. " 04/09/2024 - "Mertk has been reported to play an important role in regulating inflammation and cytoskeletal dynamics. " 02/22/2024 - "Overall, these findings underscore the pivotal role of tissue-resident AMØs in resolving O3-induced inflammation via MerTK-mediated efferocytosis." 02/13/2024 - "As a result, DAC restored joint homeostasis by resetting the transcriptomic signature of negative regulators of inflammation in synovial macrophages (MerTK, Trem2, and Cx3cr1), TREGs (Foxp3), and SFs (Pdpn and Fapα). "
3.	Atherosclerosis 01/01/2024 - "This study was designed to investigate whether endothelial MerTK and EC efferocytosis respond to blood flow patterns during atherosclerosis. " 01/01/2024 - "Conclusions: Our data suggests that blood flow patterns play an important role in regulating MerTK-mediated efferocytosis in aortic ECs, revealing a new promising therapeutic strategy with EC efferocytosis restoration to against atherosclerosis." 01/01/2024 - "Interestingly, MerTK-/-induces obvious abnormal endothelial thickening accompanied with decreased endothelial efferocytosis, promoting the development of atherosclerosis. " 01/01/2024 - "Our in vivo data of proteomics and immunostaining showed that, compared with WT group, MerTK-/- aggravates atherosclerosis in d-flow areas through upregulation of endothelial dysfunction markers (e.g. " 01/01/2024 - "Disturbed flow impairs MerTK-mediated efferocytosis in aortic endothelial cells during atherosclerosis."
4.	Fibrosis (Cirrhosis) 01/01/2019 - "These data suggest that SPP1hi macrophages contribute importantly to lung fibrosis in IPF, and that therapeutic strategies targeting MERTK and macrophage proliferation may show promise for treatment of this disease." 04/03/2024 - "Together, these data suggest that MERTK plays a role in modulating organ fibrosis and may be a potential target for treating fibrotic diseases." 04/03/2024 - "Pharmacological inhibition of MERTK reduced fibrosis in these mouse models either when initiated immediately after injury or when initiated after fibrosis was established. " 04/03/2024 - "In each of the three mouse models, disrupting the fibrosis-promoting signaling loop by reducing MERTK expression reduced organ fibrosis. " 04/03/2024 - "MERTK also induced TGFβ expression and drove TGFβ signaling resulting in a positive feedback loop that promoted fibrosis in cultured cells. "
5.	Non-alcoholic Fatty Liver Disease 09/30/2021 - "In parallel, the transcriptomic profiles of the injected MERTK+/hi M2c macrophages showed that the various genes directly or indirectly involved in NAFLD progression (e.g., SERPINE1, FADS2) were also suppressed. " 01/01/2019 - "By identifying specific targets influencing lipid metabolism and cardiovascular-related diseases, the present review highlights the role of MerTK in NAFLD-associated atherosclerotic lesions as a potential innovative therapeutic target. " 09/30/2021 - "Altogether, cell-based therapy using MERTK+/hi M2c macrophages is promising, as it ameliorates NAFLD in mice." 03/01/2016 - "The rs4374383 AA genotype, associated with lower intrahepatic expression of MERTK, is protective against F2-F4 fibrosis in patients with NAFLD. " 03/01/2016 - "The main study objective was to assess whether MERTK AA genotype influences liver fibrosis, and secondarily MERTK expression in patients with non-alcoholic fatty liver disease (NAFLD). "

Related Drugs and Biologics

1.	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)
2.	Protein-Tyrosine Kinases (Tyrosine Kinase)
3.	Phosphotransferases (Kinase)
4.	tyrosine receptor (receptor, tyrosine)
5.	c-Mer Tyrosine Kinase
6.	Ligands
7.	Interleukin-10 (Interleukin 10)
8.	Phosphatidylserines
9.	Proteins (Proteins, Gene)
10.	Lipopolysaccharides

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Radiotherapy
4.	Immunotherapy
5.	Transplantation